Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEF0117 food effect study in healthy volunteers
NCT05451017Phase 1Terminated
- Sponsor
- Aelis Farma
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aef0117 in cannabis use disorder (CUD) (2 arms), sponsored by Aelis Farma. Primary endpoints: Maximum Plasma Concentration of AEF0117 up to 312 hours, Time to Maximum Plasma Concentration of AEF0117 up to 312 hours and 3 more. Started Jan 2023; status: terminated.
02
Drugs
aef0117
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT05451017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451017.